Sei Investments Co. reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 14.4% in the second quarter, HoldingsChannel reports. The institutional investor owned 86,698 shares of the company’s stock after selling 14,601 shares during the period. Sei Investments Co.’s holdings in Novo Nordisk A/S were worth $3,999,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Dean Capital Investments Management LLC lifted its holdings in shares of Novo Nordisk A/S by 40.8% during the 1st quarter. Dean Capital Investments Management LLC now owns 5,729 shares of the company’s stock valued at $282,000 after buying an additional 1,660 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Novo Nordisk A/S by 26.4% during the 1st quarter. Oppenheimer & Co. Inc. now owns 86,897 shares of the company’s stock valued at $4,280,000 after buying an additional 18,137 shares during the last quarter. Saratoga Research & Investment Management lifted its holdings in shares of Novo Nordisk A/S by 2.5% during the 1st quarter. Saratoga Research & Investment Management now owns 1,548,679 shares of the company’s stock valued at $76,272,000 after buying an additional 38,323 shares during the last quarter. Traynor Capital Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 2.5% during the 1st quarter. Traynor Capital Management Inc. now owns 66,207 shares of the company’s stock valued at $3,260,000 after buying an additional 1,634 shares during the last quarter. Finally, Whittier Trust Co. lifted its holdings in shares of Novo Nordisk A/S by 61.5% during the 1st quarter. Whittier Trust Co. now owns 4,040 shares of the company’s stock valued at $199,000 after buying an additional 1,538 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Shares of NVO stock opened at $49.59 on Friday. Novo Nordisk A/S has a twelve month low of $44.28 and a twelve month high of $58.37. The company has a market capitalization of $121.35 billion, a P/E ratio of 19.40, a P/E/G ratio of 2.67 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 8th. The company reported $0.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.04. Novo Nordisk A/S had a return on equity of 83.32% and a net margin of 35.95%. The business had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.33 billion. research analysts predict that Novo Nordisk A/S will post 2.52 earnings per share for the current fiscal year.

The business also recently disclosed a special dividend, which was paid on Tuesday, August 28th. Investors of record on Monday, August 20th were paid a $0.4669 dividend. This represents a dividend yield of 1.72%. The ex-dividend date of this dividend was Friday, August 17th. Novo Nordisk A/S’s payout ratio is 27.78%.

A number of research analysts recently weighed in on the company. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, July 31st. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Monday, July 2nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $64.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Featured Story: What does EPS mean?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.